Vimarsana
Biggest News Aggregation in the World

Tumor Reduction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tumor Reduction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tumor Reduction Today - Breaking & Trending Today

Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? - Vimarsana News

Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?

On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule: The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT)

Source: yahoo.com
Sandalwood Oil's By-Product Halts Prostate Cancer Progress - Vimarsana News

Sandalwood Oil's By-Product Halts Prostate Cancer Progress

Discover how alpha-santalol in sandalwood oil shields against prostate cancer by reducing tumor incidence and promoting apoptosis without adverse effects.

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update - Vimarsana News

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into...

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update - Vimarsana News

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into...

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma - Vimarsana News

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line ...